Metabolic therapeutics in angina pectoris: History revisited with perhexiline

European Journal of Cardiovascular Nursing

Volumn 5, Issue 2, 2006, Pages 175-184

  Inglis, Sally ^a   Stewart, Simon ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Etomoxir; Nursing management; Perhexiline; Pharmacology; Ranolazine; Refractory angina; Trimetazidine

Indexed keywords

ETOMOXIR; INSULIN; PERHEXILINE MALEATE; RANOLAZINE; SEROTONIN UPTAKE INHIBITOR; TRIMETAZIDINE;

ACUTE HEART INFARCTION; ANGINA PECTORIS; AORTA STENOSIS; ARTICLE; DIABETES MELLITUS; DISEASE SEVERITY; DIZZINESS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFORMATION; DRUG METABOLISM; DRUG MONITORING; GENETIC POLYMORPHISM; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LETHARGY; LIVER CIRRHOSIS; LIVER INJURY; LIVER TOXICITY; NAUSEA; NEUROTOXICITY; NURSE; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING ASSESSMENT; NURSING INTERVENTION; PATIENT ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VOMITING; WEIGHT REDUCTION;

ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CARNITINE O-PALMITOYLTRANSFERASE; DRUG MONITORING; EPOXY COMPOUNDS; FATTY ACIDS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT EDUCATION; PATIENT SELECTION; PERHEXILINE; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 33646188203     PISSN: 14745151     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcnurse.2006.01.001     Document Type: Article

References (59)

1. Stewart S., Murphy N., Walker A., McGuire A., and McMurray J.J. The current cost of angina pectoris to the National Health Service in the UK. Heart 89 (2003) 848-853
2. Murphy N.F., MacIntyre K., Capewell S., Stewart S., Pell J., Chalmers J., et al. Hospital discharge rates for suspected acute coronary syndromes between 1990-2000: population based analysis. BMJ 328 (2004) 1413-1414
3. Stewart S. Refractory to medical treatment but not to nursing care: can we do more for patients with chronic angina pectoris?. Eur J Cardiovasc Nurs 2 (2003) 169-170
4. Mannheimer C., Camici P., Chester M.R., Collins A., DeJongste M., Eliasson T., et al. The problem of chronic refractory angina. Report from the ESC joint study group on the treatment of refractory angina. Eur Heart J 23 (2002) 355-370
5. Lewin R.J. Improving quality of life in patients with angina. Heart 82 (1999) 654-655
6. Lewin R.J., Furze G., Robinson J., Griffith K., Wiseman S., Pye M., et al. A randomised controlled trial of a self-management plan for patients with newly diagnosed angina. Br J Gen Pract 52 (2002) 194-201
7. Kim M.C., Kini A., and Sharma S.K. Refractory angina pectoris mechanism and therapeutic options. J Am Coll Cardiol 39 6 (2002) 923-934
8. Campeau L. Grading of angina pectoris (letter). Circulation 54 (1976) 522-523
9. Lee L., Horowitz J.D., and Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 25 (2004) 634-641
10. Unger S.A., Robinson M.A., and Horowitz J.D. Perhexiline improves symptomatic status in elderly patients with aortic stenosis. Aust N Z J Med 27 1 (1997) 24-28
11. Burns-Cox C.J., Chandrasekhar K.P., Ikram H., Pierce T.H., Pilcher J., Quinlan C.D., et al. Clinical evaluation of perhexiline maleate in patients with angina pectoris. BMJ 787 (1974) 586-588
12. Bleifer D.J., Bleifer S.B., and Okun R. Perhexiline maleate in angina pectoris. Geriatrics 27 9 (1972) 109-115
13. Gitlin N., and Nellen M. Perhexiline maleate in the treatment of angina pectoris: a double blind trial. Postgrad Med J (1973) 100-104 [Apr Suppl.]
14. White H.D., and Lowe J.B. Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. Int J Cardiol 3 (1983) 145-155
15. Armstrong M.L. A comparative study of perhexiline, beta-adrenergic blocking agents and placebos in the management of angina pectoris. Postgrad Med J 3 49 Suppl. (1973 (Apr.)) 108-111
16. Shah R.R., Oates N.S., Idle J.R., Smith R.L., and Lockhart J.D.F. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 284 (1982) 295-299
17. Morgan M.Y., Reshef R., Shah R.R., Oates N.S., Smith R.L., and Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25 (1984) 1057-1064
18. Horowitz J.D., Sia S.T.B., Macdonald P.S., Goble A.J., and Louis W.J. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol 13 (1986) 219-229
19. Cole P.L., Beamer A.D., McGowan N., Cantillon C.O., Benfell K., Kelly R.A., et al. Efficacy and safety of perhexiline maleate in refractory angina: a double-blind placebo-controlled trial of a novel antianginal agent. Circulation 81 (1990) 1260-1270
20. Cho Y.W., Belej M., and Aviado D.M. Pharmacology of a new antianginal drug: perhexiline coronary circulation and myocardial metabolism. Chest 56 6 (1970) 577-585
21. Kennedy J.A., Unger S.A., and Horowitz J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52 (1996) 273-280
22. Stewart S., Voss D.W., Northey D.L., and Horowitz J.D. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit 18 (1996) 635-639
23. Willoughby S.R., Stewart S., Chirkov Y.Y., Kennedy J.A., Holmes A.S., and Horowitz J.D. Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J 23 (2002) 1946-1954
24. Stanley W.C. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs 11 5 (2002) 615-629
25. Lopascuk G.D., Belke D.D., Gamble J., Itoi T., and Schönekess B.O. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta (1994) 263-276
26. Stanley W.C., and Chandler M. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 7 (2002) 115-130
27. Liedtke A.J. Alterations of carbohydrate and lipid metabolism in the acutely ischaemic heart. Prog Cardiovasc Dis 23 5 (1981) 321-336
28. Pornin M., Harpey C., Allal, Sellier P., and Ourbak P. Lack of efforts of trimetazadine on systemic hemodynamics in patients with coronary disease: a placebo-controlled study. Clin Trials Metaanal 29 1 (1994) 49-56
29. Kantor P.F., Lucien A., Kozak R., and Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 5 (2000) 580-588
30. MacInnes A., Fairman D.A., Binding P., Rhodes J., Wyatt M.J., Phelan A., et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93 3 (2003) e33-e37
31. Kennedy J.A., and Horowitz J.D. Effect of trimetazine on carnitine palmitoyltransferase-1 in the rat heart. Cardiovasc Drugs Ther 12 4 (1998) 359-363
32. Szwed H., Sadowski Z., Elikowski W., Koronkiewicz A., Mamcarz A., Orszulak W., et al. Combination treatment in stable effort angina using trimetazadine and metoprolol: results of a randomised, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 22 24 (2001) 2267-2274
33. Marzilli M., and Klein W.W. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomised, double-blind, controlled trials. Coron Artery Dis 14 2 (2003) 171-179
34. McCormack J.G., Barr R., Wolff A.A., and Lopaschuk G.D. Ranolazine stimulates glucose oxidation in normotoxic, ischaemic, and reperfused ischaemic rat hearts. Circulation 93 1 (1996) 135-142
35. Wolff A.A. The MARISA Investigators and CV Therapeutics. MARISA: monotherapy assessment of ranolazine in stable angina. J Am Coll Cardiol 35 Suppl. A (2000) 408A
36. Chaitman B.R., Pepine C.J., Parker J.O., Skopal J., Chumakova G., Kuch J., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291 3 (2004) 309-316
37. Reaven G.M., Chang H., and Hoffman B.B. Additive hypoglycaemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes 37 1 (1988) 28-32
38. Lopascuk G.D., Wall S.R., Olley P.M., and Davies N.J. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischaemic injury independent of changes in long chain acylcarnitine. Circ Res 63 6 (1988) 1036-1043
39. Schmidt-Schweda S., and Holubarsch C. First clinical trail with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 99 1 (2000) 27-35
40. Malmberg K., Ryden L., Efendic S., Herlitz J., Nicol P., Waldenstrom A., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26 (1995) 57-65
41. Malmberg K. Role of insulin-glucose infusion in outcomes after acute myocardial infarction: the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Endocr Pract 10 S2 (2004) 13-16
42. Killalea S.M., and Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischaemic heart disease. Am J Cardiovasc Drugs 1 3 (2001) 193-204
43. Singlas E., Goujet M.A., and Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol 14 (1978) 195-201
44. Pilcher J., Cooper J.D.H., Turnell D.C., Matenga J., Paul R., and Lockhart J.D. Investigations of long-term treatment with perhexiline maleate using therapeutic monitoring and electromyography. Ther Drug Monit 7 (1985) 54-60
45. Deschamps D., DeBeco V., Fisch C., Fromenty B., Guillouzo A., and Pessaayre D. Inhibition by perhexiline of oxidative phosphorylation and β-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 19 4 (1994) 948-961
46. Horowitz J.D., Morris P.M., Drummer O.H., Goble A.J., and Louis W.J. High-performance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci 70 3 (1981) 320-322
47. Cooper J.D.H., Turnell D.C., Pilcher J., and Lockhart D. Therapeutic monitoring of the antianginal drug perhexiline maleate. Ann Clin Biochem 22 (1985) 614-617
48. Wright G.J., Leeson G.A., Zeiger A.V., and Lang J.F. The absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad Med J (1973) 8-15 [April Suppl.]
49. Cooper R.G., Harper G., Price A.H., Evans D.A.P., and Lockhart D. Simultaneous determination of perhexiline and its monohydroxy metabolites in biological fluids by gas chromatography-electron-capture detection. J Chromatogr 381 (1986) 305-314
50. Cooper R.G., Evans D.A.P., and Whibley E.J. Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 21 (1984) 27-33
51. Zanger U.M., Raimundo S., and Eichelbaum M. Cytochrome P45 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol 369 (2004) 23-37
52. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet North Am Ed 356 (2000) 1667-1671
53. Bertilsson L., Dahl M.L., Dalén P., and Al-Shurbaji A. Molecular Genetics of CYP2D6: clinical relevance with focus on psychotrophic drugs. Br J Clin Pharmacol 53 (2002) 111-122
54. Aklillu E., Persson I., Bertilsson L., Johansson I., Rodrigues F., and Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolisers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278 1 (1996) 441-446
55. Alderman C.P., Hundertmark J.D., and Soetratma T.W. Interaction of serotonin re-uptake inhibitors with perhexiline. Aust N Z J Psychiatry 31 (1997) 601-603
56. Stewart S. Caring for patients with acute myocardial ischaemia: the perhexiline maleate experience. Dimens Crit Care Nurs 14 3 (1995) 127-135
57. Cooper R.G., Evans D.A.P., and Price A.H. Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 32 (1987) 569-576
58. MIMS Australia. Perhexiline maleate MIMS Abbreviated Prescribing Information. [Online] 2003 [cited 2005 Aug 19]. Available from URL: http://mims.hcn.net.au via the University of Queensland Library.
59. Horowitz J.D., Button I.K., and Wing L. Is perhexiline essential for the optimal management of angina pectoris?. Aust N Z J Med 25 (1995) 111-113